Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Amit S Kalgutkar & John R Soglia. (2005) Minimising the potential for metabolic activation in drug discovery. Expert Opinion on Drug Metabolism & Toxicology 1:1, pages 91-142.
Read now
Read now
Shufeng Zhou, Eli Chan, Wei Duan, Min Huang & Yu-Zong Chen. (2005) Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance. Drug Metabolism Reviews 37:1, pages 41-213.
Read now
Read now
Jennie L. Walgren, Michael D. Mitchell & David C. Thompson. (2005) Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity. Critical Reviews in Toxicology 35:4, pages 325-361.
Read now
Read now
Slobodan Rendic. (2002) Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabolism Reviews 34:1-2, pages 83-448.
Read now
Read now
Slobodan Rendic & Frederick J. Di Carlo. (1997) Human Cytochrome P450 Enzymes: A Status Report Summarizing Their Reactions, Substrates, Inducers, and Inhibitors. Drug Metabolism Reviews 29:1-2, pages 413-580.
Read now
Read now
D. K. Monteith, M. R. Emmerling, J. Garvin & J. C. Theiss. (1996) Cytotoxicity Study of Tacrine, Structurally and Pharmacologically Related Compounds Using Rat Hepatocytes. Drug and Chemical Toxicology 19:1-2, pages 71-84.
Read now
Read now
SK. Bezek, M. Kukan, W. F. Pool & T. F. Woolf. (1996) The effect of cytochromes P4501A induction and inhibition on the disposition of the cognition activator tacrine in rat hepatic preparations. Xenobiotica 26:9, pages 935-946.
Read now
Read now
Articles from other publishers (24)
Martin Novak, Marie Vajrychova, Stefania Koutsilieri, Despoina-Christina Sismanoglou, Tereza Kobrlova, Lukas Prchal, Barbora Svobodova, Jan Korabecny, Tomas Zarybnicky, Lucie Raisova-Stuchlikova, Lenka Skalova, Volker M. Lauschke, Radim Kučera & Ondrej Soukup. (2023) Tacrine First-Phase Biotransformation and Associated Hepatotoxicity: A Possible Way to Avoid Quinone Methide Formation. ACS Chemical Biology 18:9, pages 1993-2002.
Crossref
Crossref
M. Novak, B. Svobodova, J. Konecny, A. Kuratkova, L. Nevosadova, L. Prchal, J. Korabecny, V.M. Lauschke, O. Soukup & R. Kučera. (2023) UHPLC-Orbitrap study of the first phase tacrine in vitro metabolites and related Alzheimer's drug candidates using human liver microsomes. Journal of Pharmaceutical and Biomedical Analysis 224, pages 115154.
Crossref
Crossref
Albert P. Li. 2021. Transporters and Drug‐Metabolizing Enzymes in Drug Toxicity. Transporters and Drug‐Metabolizing Enzymes in Drug Toxicity
79
137
.
Albert P. Li. 2021. Transporters and Drug‐Metabolizing Enzymes in Drug Toxicity. Transporters and Drug‐Metabolizing Enzymes in Drug Toxicity
41
77
.
Tyler B. Hughes, Na Le Dang, Ayush Kumar, Noah R. Flynn & S. Joshua Swamidass. (2020) Metabolic Forest: Predicting the Diverse Structures of Drug Metabolites. Journal of Chemical Information and Modeling 60:10, pages 4702-4716.
Crossref
Crossref
Mansour K. Gatasheh, S. Kannan, K. Hemalatha & N. Imrana. (2017) Proflavine an acridine DNA intercalating agent and strong antimicrobial possessing potential properties of carcinogen. Karbala International Journal of Modern Science 3:4, pages 272-278.
Crossref
Crossref
Katharina Zenger, Xinyu Chen, Michael Decker & Birgit Kraus. (2013) In-vitro stability and metabolism of a tacrine–silibinin codrug. Journal of Pharmacy and Pharmacology 65:12, pages 1765-1772.
Crossref
Crossref
Alexander V. LyubimovHayley M. Webb, Sophie Regan, Daniel J. Antoine, Nicola Lane, Rachel J. Walsh, Abhishek Srivastava, Philip Starkey‐Lewis, Craig Benson, Dominic P. Williams, Hugh Laverty, Christopher Goldring & B. Kevin Park. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
44
.
Shuai Qian, Siu Kwan Wo & Zhong Zuo. (2012) Pharmacokinetics and brain dispositions of tacrine and its major bioactive monohydroxylated metabolites in rats. Journal of Pharmaceutical and Biomedical Analysis 61, pages 57-63.
Crossref
Crossref
Daniel Silva, Mourad Chioua, Abdelouahid Samadi, M. Carmo Carreiras, María-Luisa Jimeno, Eduarda Mendes, Cristóbal de los Ríos, Alejandro Romero, Mercedes Villarroya, Manuela G. López & José Marco-Contelles. (2011) Synthesis and pharmacological assessment of diversely substituted pyrazolo[3,4-b]quinoline, and benzo[b]pyrazolo[4,3-g][1,8]naphthyridine derivatives. European Journal of Medicinal Chemistry 46:9, pages 4676-4681.
Crossref
Crossref
John S. WalshGerald T. Miwa. (2011) Bioactivation of Drugs: Risk and Drug Design. Annual Review of Pharmacology and Toxicology 51:1, pages 145-167.
Crossref
Crossref
Thomas A. Baillie & Allan E. Rettie. (2011) Role of Biotransformation in Drug-Induced Toxicity: Influence of Intra- and Inter-Species Differences in Drug Metabolism. Drug Metabolism and Pharmacokinetics 26:1, pages 15-29.
Crossref
Crossref
Michael A. Mohutsky, Annette Romeike, Vince Meador, William M. Lee, John Fowler & Sabine Francke-Carroll. (2010) Hepatic Drug-Metabolizing Enzyme Induction and Implications for Preclinical and Clinical Risk Assessment. Toxicologic Pathology 38:5, pages 799-809.
Crossref
Crossref
Jong-Hyuk Sung, Soon-Sun Hong, Sung-Hoon Ahn, Hong Li, Seung-Yong Seo, Chul-Hong Park, Byung-Soon Park & Suk-Jae Chung. (2006) Mechanism for increased bioavailability of tacrine in fasted rats. Journal of Pharmacy and Pharmacology 58:5, pages 643-649.
Crossref
Crossref
Daniel F. Carr, Ana Alfirevic, Jonathan D. Tugwood, Bryan J. Barratt, James Sherwood, John Smith, Munir Pirmohamed & B. Kevin Park. (2007) Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity. Pharmacogenetics and Genomics 17:11, pages 961-972.
Crossref
Crossref
John S. Walsh. 2006. Optimizing the “Drug-Like” Properties of Leads in Drug Discovery. Optimizing the “Drug-Like” Properties of Leads in Drug Discovery
49
80
.
Joanna Z. Peng, Rory P. Remmel & Ronald J. Sawchuk. (2004) INHIBITION OF MURINE CYTOCHROME P4501A BY TACRINE: IN VITRO STUDIES. Drug Metabolism and Disposition 32:8, pages 805-812.
Crossref
Crossref
David F.V. Lewis, Brian G. Lake, Stephen G. George, Maurice Dickins, Peter J. Eddershaw, Michael H. Tarbit, Alan P. Beresford, Peter S. Goldfarb & F.Peter Guengerich. (1999) Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102. Toxicology 139:1-2, pages 53-79.
Crossref
Crossref
William Pool. 1999. Handbook of Drug Metabolism. Handbook of Drug Metabolism
577
587
.
Munir Pirmohamed & B Park. 1999. Handbook of Drug Metabolism. Handbook of Drug Metabolism
443
476
.
Errol Zeiger, Gregory Erexson, Kristien Mortelmans & A Thilagar. (1997) Genetic toxicity studies of 1,2,3,4-tetrahydro-9-acridinamine (tacrine). Mutation Research/Genetic Toxicology and Environmental Mutagenesis 393:3, pages 189-197.
Crossref
Crossref
Laurent Becquemont, Isabelle Ragueneau, Marie Annick Le Bot, Christian Riche, Christian Funck-Brentano & Patrice Jaillon. (1997) Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans*. Clinical Pharmacology & Therapeutics 61:6, pages 619-627.
Crossref
Crossref
T. F. Woolf, W. P. Pool, R. M. Walker & D. K. Monteith. 1996. Drug-Induced Hepatotoxicity. Drug-Induced Hepatotoxicity
395
410
.
B.Kevin Park, Munir Pirmohamed & Neil R. Kitteringham. (1995) The role of cytochrome P450 enzymes in hepatic and extrahepatic human drug toxicity. Pharmacology & Therapeutics 68:3, pages 385-424.
Crossref
Crossref